At a glance
A combined research record involving GHK-Cu, KPV, BPC-157 and a TB-500 preparation.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together GHK-Cu, KPV, BPC-157 and a TB-500 preparation. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][2][3]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][3][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of KLOW.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 80 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
This multi-peptide blend provides synergistic regenerative, anti-inflammatory, and tissue-repair support. The following titration schedule allows gradual introduction of each component. Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to maintain measurable volumes. For ≤10-unit (≤0.10 mL) administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support tissue repair, reduce inflammation, and promote regeneration through synergistic peptide action[1][3][5][7].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: Gradual titration from low to moderate doses based on individual response.
- Reconstitution: 3.0 mL per 80 mg vial (~26.7 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 7.5 units daily (0.075 mL) for initial assessment period.
- Increase: Progress to 15 units by Week 3, then 22.5 units by Week 5 as tolerated.
- Maintenance: 15 units daily for extended protocols.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[9].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14–28 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10][11].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].
- Apply gentle pressure after withdrawal; do not massage the injection site.
Materials & quantity planning
Source materials checklist · 80 mg
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (KLOW, 80 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
- Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 80 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Thymosin beta 4 accelerates wound healing (Philp et al., 1999) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PubMed — Thymosin β4 promotes dermal healing in preclinical models and clinical trials (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
PMC — Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PMC — Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PMC — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PMC — Orally targeted delivery of tripeptide KPV via HA-functionalized nanoparticles alleviates ulcerative colitis (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Research publication
PMC — Regenerative and protective actions of the GHK-Cu peptide in light of new gene data (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PMC — GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Source document
Sigma-Aldrich — Handling and storage guidelines for peptides and proteins (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous injection technique guidelines (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
CDC — Vaccine administration best practices (aspiration not recommended for SC injections) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Public health resource
NCBI Bookshelf — Chapter 18: Administration of parenteral medications (injection technique) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
PubMed — Thymosin β4: a multi-functional regenerative peptide (basic properties and clinical applications) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 14
Research publication
PMC — The potential of GHK as an anti-aging peptide (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.